Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brelovitug - Mirum Pharmaceuticals

Next Previous
Drug Profile

Brelovitug - Mirum Pharmaceuticals

Alternative Names: BJT-778; BTG

Latest Information Update: 05 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Mirum Pharmaceuticals
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis B surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis D
  • Phase II Hepatitis B

Most Recent Events

  • 30 May 2026 Efficacy data from phase II/III AZURE 1 clinical trials in Hepatitis D released by Mirum Phamraceuticals
  • 29 Apr 2026 3929679: patent info added
  • 05 Mar 2026 Mirum Pharmaceuticals completes enrolment in the AZURE-1 trial for Hepatitis D (Monotherapy, Treatment-naive) in Australia, Canada, New Zealand, Pakistan, Serbia, Turkey, Moldova, US, Bulgaria, Georgia, Israel and Ukraine (NCT06907290)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top